Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Sep 20;5(10):e1226718. doi: 10.1080/2162402X.2016.1226718

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2016 Taylor & Francis Group, LLC

PMC Copyright notice

Figure 2. — Effect of sorafenib treatment on ERK phosphorylation levels and absolute number of EPC. Pre-treatment samples of PBMC from HCC patients were treated with different concentrations of sorafenib (0–20 μM) in vitro and (A) the number of pERK⁺ EPC and (C) the absolute number of EPC were measured as described in Materials and Methods section. Each symbol () represents an individual HCC patient and lines represent mean values for the group. (B) The number of pERK⁺ EPC/mL and (D) absolute number of EPC in HCC patients before (▪) or after treatment (•) with sorafenib (in vivo) was measured as described in the materials and methods.

Inline graphic — Effect of sorafenib treatment on ERK phosphorylation levels and absolute number of EPC. Pre-treatment samples of PBMC from HCC patients were treated with different concentrations of sorafenib (0–20 μM) in vitro and (A) the number of pERK⁺ EPC and (C) the absolute number of EPC were measured as described in Materials and Methods section. Each symbol () represents an individual HCC patient and lines represent mean values for the group. (B) The number of pERK⁺ EPC/mL and (D) absolute number of EPC in HCC patients before (▪) or after treatment (•) with sorafenib (in vivo) was measured as described in the materials and methods.